Posttraumatic Stress Disorder: From Neurobiology to Treatment
Posttraumatic Stress Disorder: From Neurobiology to Treatment
Editor/Author
Bremner, J. Douglas
Publication Year: 2016
Publisher: Wiley
Single-User Purchase Price:
$130.00

Unlimited-User Purchase Price:
$195.00
ISBN: 978-1-118-35611-1
Category: Psychology
Image Count:
42
Book Status: Available
Table of Contents
Posttraumatic Stress Disorder: From Neurobiology to Treatment presents a comprehensive look at this key neuropsychiatric disorder. The text examines the neurobiological basis of post-traumatic stress and how our understanding of the basic elements of the disease have informed and been translated into new and existing treatment options.
This book is found in the following Credo Collections:
Table of Contents
- List of Illustrations
- List of Tables
- List of contributors
- Introduction
- Reference
- Section I: Preclinical sciences of stress
- Chapter 1: Posttraumatic stress disorder: from neurobiology to clinical presentation
- 1.1 PTSD: prevalence, risk factors, and etiology
- 1.2 Neurobiology of PTSD
- 1.3 Synthesis of findings: from neurobiology to treatment of PTSD
- References
- Chapter 2: The epidemiology of posttraumatic stress disorder in children and adolescents: a critical review
- 2.1 Introduction
- 2.2 Studies involving general population surveys
- 2.3 Prevalence of exposure to traumatic events in youth populations
- 2.4 Community surveys assessing child-adolescent PTSD prevalence
- 2.5 Childhood/adolescent PTSD rates according to type of trauma
- 2.6 Child-adolescent PTSD and comorbid disorders
- 2.7 Risk factors associated with child-adolescent PTSD
- 2.8 Summary
- 2.9 Acknowledgement
- References
- Chapter 3: Early life stress and development: preclinical science
- 3.1 Overview
- 3.2 Early life stress and the hypothalamic–pituitary–adrenal (HPA) axis
- 3.3 Rodent models of early life stress/trauma
- 3.4 Non-human primate models of early life stress/trauma
- 3.5 Impact of early life stress on prefrontal-limbic brain circuits across species: biological and evolutionary mechanisms
- 3.6 Conclusions
- 3.7 Acknowledgements
- References
- Chapter 4: Amygdala contributions to fear and safety conditioning: insights into PTSD from an animal model across development
- 4.1 Introduction
- 4.2 Stress and defensive responding
- 4.3 Fear conditioning
- 4.4 Safety conditioning
- 4.5 Ontogeny of fear and safety conditioning
- 4.6 Implications for PTSD
- 4.7 Conclusion
- 4.8 Acknowledgement
- References
- Chapter 5: Preclinical evidence for benzodiazepine receptor involvement in the pathophysiology of PTSD, comorbid substance abuse, and alcoholism
- 5.1 Introduction
- 5.2 Stress and the Benzodiazepine Receptor
- 5.3 Interaction of Stress, Alcohol Intake and the Benzodiazepine Rector
- 5.4 Stress, Drug Abuse and the Benzodiazepine Receptor
- 5.5 Translation from Neurobiology to PTSD
- 5.6 Conclusions
- References
- Chapter 6: Psychosocial predator stress model of PTSD based on clinically relevant risk factors for trauma-induced psychopathology
- 6.1 Introduction
- 6.2 General characteristics of PTSD
- 6.3 Preclinical models of PTSD
- 6.4 Psychosocial predator stress model of PTSD
- 6.5 Summary: the challenge of modeling PTSD in animals
- 6.6 Acknowledgements
- References
- Chapter 7: Coping with stress in wild birds – the evolutionary foundations of stress responses
- 7.1 Introduction
- 7.2 Physiological changes associated with chronic stress in wild birds
- 7.3 Lessons from wild birds
- 7.4 Conclusions
- 7.5 Acknowledgements
- References
- Chapter 8: Stress, fear, and memory in healthy individuals
- 8.1 Introduction
- 8.2 Time-dependent effects of stress on episodic memory in healthy humans
- 8.3 Stress and fear conditioning in humans
- 8.4 Stress-induced modulation of multiple memory systems
- 8.5 Stress and memory in healthy subjects: implications for PTSD
- References
- Section II: Neurobiology of PTSD
- Chapter 9: Neurotransmitter, neurohormonal, and neuropeptidal function in stress and PTSD
- 9.1 Introduction
- 9.2 Noradrenergic system
- 9.3 HPA axis
- 9.4 PTSD and inflammation
- 9.5 Acetylcholine and vagal nerve function
- 9.6 Dopaminergic system
- 9.7 NMDA
- 9.8 Serotonin
- 9.9 GABA/benzodiazepine system
- 9.10 Opioid peptides
- 9.11 Neurotensin
- 9.12 Somatostatin
- 9.13 Cholecystokinin
- 9.14 Neuropeptide Y
- 9.15 Galanin
- 9.16 Ghrelin
- 9.17 Substance P
- 9.18 Vasoactive intestinal peptide
- 9.19 Vasopressin and oxytocin
- 9.20 Neurosteroids and neurohormones
- 9.21 Conclusions
- References
- Chapter 10: Genomics of PTSD
- 10.1 Introduction
- 10.2 Genetic studies in PTSD
- 10.3 Gene–environment interaction studies in PTSD
- 10.4 Epigenetic and gene expression studies in PTSD
- 10.5 Conclusions
- References
- Chapter 11: Cortisol and the Hypothalamic–Pituitary–Adrenal Axis in PTSD
- 11.1 Introduction
- 11.2 HPA axis and the stress response
- 11.3 HPA axis alterations in PTSD
- 11.4 HPA feedback functioning and GR sensitivity
- 11.5 Gender, PTSD, and HPA axis activity
- 11.6 HPA alterations as a risk factor for PTSD
- 11.7 Genetic and epigenetic influences on GR sensitivity
- 11.8 Modifying glucocorticoid responsiveness: implications for prevention and treatment
- 11.9 Conclusion
- References
- Chapter 12: Neuroimaging of PTSD
- 12.1 History and background
- 12.2 Neural circuits of PTSD
- 12.3 Changes in brain structure and cognitive functioning in PTSD
- 12.4 Neurohormonal responses to PTSD
- 12.5 Functional neuroimaging studies in PTSD
- 12.6 Neuroreceptor Studies in PTSD
- 12.7 Conclusions
- References
- Section III: PTSD and co-occuring conditions
- Chapter 13: PTSD and mild traumatic brain injury
- 13.1 Introduction
- 13.2 Mild TBI
- 13.3 Posttraumatic stress disorder
- 13.4 Overlap between mTBI and PTSD
- 13.5 Summary and conclusions
- References
- Chapter 14: Stress-related psychopathology and pain
- 14.1 Introduction
- 14.2 Depression
- 14.3 Schizophrenia
- 14.4 Anorexia nervosa
- 14.5 Borderline personality disorder
- 14.6 Post-traumatic stress disorder
- 14.7 Conclusion
- References
- Chapter 15: Stress and health
- 15.1 Introduction
- 15.2 Stress and cardiovascular disease
- 15.3 Depression and cardiovascular disease
- 15.4 PTSD and cardiovascular disease
- 15.5 Potential mechanisms linking stress to cardiovascular disease
- 15.6 Mechanisms through which depression and PTSD may increase CVD risk
- 15.7 Stress, PTSD and functional pain disorders
- 15.8 Conclusions
- References
- Section IV: PTSD: from neurobiology to treatment
- Chapter 16: Pharmacotherapy for PTSD: effects on PTSD symptoms and the brain
- 16.1 Introduction
- 16.2 Agents acting on the GABA–benzodiazepine receptor complex
- 16.3 Agents acting on norepinephrine and serotonin receptors
- 16.4 Tricyclic and monoamine oxidase inhibitor antidepressants
- 16.5 Medications with other mechanisms of action
- 16.6 Selective norepinephrine reuptake inhibitors
- 16.7 Selective serotonin reuptake inhibitors
- 16.8 Antidepressants with actions on norepinephrine and epinephrine reuptake
- 16.9 Mood stabilizers
- 16.10 Antipsychotic medications
- 16.11 Glutamatergic agents
- 16.12 MDMA
- 16.13 Effect of pharmacotherapy on the brain and neurobiology in PTSD
- 16.14 Conclusions
- References
- Chapter 17: Effects of psychotherapy for psychological trauma on PTSD symptoms and the brain
- 17.1 Psychotherapy for psychological trauma
- 17.2 The neuroscience of early interventions for trauma
- 17.3 Psychological therapy for psychological trauma
- 17.4 Effects of psychotherapy on the brain
- 17.5 Brain imaging of psychotherapy in PTSD
- 17.6 Conclusions
- References